logo
  

Merck : EU Approves KEYTRUDA Plus LENVIMA For Certain Types Of Endometrial Carcinoma, Advanced RCC

The European Commission has approved the combination of KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation, Merck (MRK) and Eisai said in a statement.

The approval marks the first combination of an immunotherapy with a tyrosine kinase inhibitor approved in Europe for these patients with advanced or recurrent endometrial carcinoma.

The approval was based on results from the pivotal Phase 3 KEYNOTE-775/Study 309 trial, in which KEYTRUDA plus LENVIMA demonstrated statistically significant improvements in overall survival, reducing the risk of death by 38%, and progression-free survival, reducing the risk of disease progression or death by 44%, versus chemotherapy.

In a separate press release, Merck and Eisai said that the European Commission has approved the combination of KEYTRUDA, plus LENVIMA for the first-line treatment of adult patients with advanced renal cell carcinoma or RCC.

The approval for advanced RCC is based on results from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, in which KEYTRUDA plus LENVIMA demonstrated statistically significant improvements versus sunitinib in the efficacy outcome measures of progression-free survival, reducing the risk of disease progression or death by 61% with a median PFS of 23.9 months versus 9.2 months for sunitinib, and overall survival, reducing the risk of death by 34% versus sunitinib.

The approval allows marketing of KEYTRUDA plus LENVIMA in all 27 EU member states plus Iceland, Liechtenstein, Norway and Northern Ireland.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft Corp. (MSFT) said it plans to acquire Activision Blizzard Inc. (ATVI) for $95.00 per share, in an all-cash deal valued at $68.7 billion, inclusive of Activision Blizzard's net cash. The planned acquisition includes iconic franchises from the Activision, Blizzard and King studios like Warcraft,... Goldman Sachs Group Inc. reported Tuesday that profit for the fourth quarter declined 13 percent from last year, reflecting an 8 percent drop in net revenues, higher operating expenses and higher provisions for bad loans. Earnings for the quarter missed analysts' expectations, but quarterly revenues topped it. Amazon has dropped its earlier plan to stop accepting credit cards issued by Visa Inc. in the United Kingdom. The e-commerce giant said it is working on a potential solution with the payments processor to resolve a dispute over the payment fees. In an email to customers, the company reportedly said, "The expected change regarding the use of Visa credit cards on Amazon.co.uk will no longer take...
Follow RTT